Robert W. Baird initiated coverage on Science 37 with a new price target
$SNCE
Computer Software: Prepackaged Software
Technology
Robert W. Baird initiated coverage of Science 37 with a rating of Outperform and set a new price target of $15.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $15.00 | Buy | Lake Street |
| 11/1/2021 | $15.00 | Outperform | Robert W. Baird |
| 11/1/2021 | Outperform | William Blair | |
| 11/1/2021 | $15.00 | Outperform | Baird |
| 10/22/2021 | $14.00 | Outperform | Cowen & Co. |
Baird analyst Eric Coldwell downgrades Science 37 Hldgs (NASDAQ:SNCE) from Outperform to Neutral and announces $5.75 price target.
U.S. stocks traded slightly higher toward the end of trading, with the Nasdaq Composite gaining around 75 points on Monday. The Dow traded up 0.03% to 38,121.11 while the NASDAQ rose 0.48% to 15,529.84. The S&P 500 also rose, gaining, 0.19% to 4,900.27. Check This Out: American Airlines To Rally Around 32%? Here Are 10 Top Analyst Forecasts For Monday Leading and Lagging Sectors Consumer discretionary shares rose by 0.6% on Monday. In trading on Monday, energy shares fell by 0.8%. Top Headline The Federal Reserve Bank of Dallas’s general business activity index for manufacturing in Texas fell 17 points to a reading of -27.4 in January. Equities Trading UP Science
Lake Street initiated coverage of Science 37 with a rating of Buy and set a new price target of $15.00
Robert W. Baird initiated coverage of Science 37 with a rating of Outperform and set a new price target of $15.00
William Blair initiated coverage of Science 37 Hldgs with a rating of Outperform
RESEARCH TRIANGLE PARK, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, announced today Erica Prowisor as SVP of Patient and Provider Networks to accelerate patient recruitment, ensure participant diversity and gain operational efficiencies. Erica has been forging new ground as a leader in patient recruitment for nearly 20 years, most notably with IQVIA where she was Global Head of Recruitment and Retention for more than three years and led the company's direct-to-patient recruitment and retention efforts. Prior to IQVIA, Erica spent 11 years with Acurian through the acquisition by PPD where she was Head of Enrollment Opera
RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™, today announced the appointment of Irena Lambridis as its Global Head of Quality Assurance & Compliance. Irena will be responsible for overseeing quality and compliance across all functions, including the Company's newly announced global Centers of Excellence in India, Pakistan, and Slovakia. This key appointment reflects Science 37's commitment to quality as it expands operations globally. Irena brings nearly two decades of experience in clinical research quality assurance, having held senior leadership positions at KCR and Novella Clinical (now IQVIA
OpenSesame today announced it has appointed Tamar Elkeles, PhD, and Emily Rollins to its Board of Directors. Dr. Elkeles is a highly regarded Chief Human Resources Officer and thought leader, advising globally on Talent, Learning, Human Resources, and Organization Development. Ms. Rollins has served hundreds of companies during her career at Deloitte, where she held various leadership positions in their U.S. Technology, Media, and Telecommunications practice, Audit Innovation and Transformation, and Diversity and Inclusion initiatives. Both executives bring decades of experience in technology, talent, finance, and governance to OpenSesame. Dr. Elkeles has spent 30 years in the human capit
MORRISVILLE, N.C., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, was a key enrolling site for the primary completion of a Phase 3 rare disease trial sponsored by global biopharmaceutical company, GSK. The hepatology study of an investigational medicine for cholestatic pruritus in primary biliary cholangitis (PBC) required 230 global participants, of which Science 37 was able to contribute almost half (17 - 47%) of the U.S. enrollment for the study. Recognizing that the available participant population for rare disease studies is often extremely limited and dispersed globally, GSK welcomed an innovative approach to expanding trial
MORRISVILLE, N.C., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, today announced the grand opening of its new, 19,000-square-foot corporate headquarters in Morrisville, North Carolina, in the heart of Research Triangle Park. The new, state-of-the-art facility, will serve as a hub for all Science 37 operations, enabling cross-functional teams with greater opportunities for collaborative problem-solving and integrated solution delivery. Centralizing operations in one facility will enable Science 37 to deliver patient recruitment and study conduct support on behalf of clinical trial sponsors with greater consistency, speed, and quality
MORRISVILLE, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Science 37, a leader in enhancing patient access to clinical trials, disclosed the final figures resulting from its partnership with a biopharmaceutical company focused on infectious disease prevention research. Science 37 contributed to the recruitment and enrollment of an immunocompromised patient cohort for the sponsor's Phase 3 trial. Leveraging its proprietary Virtual Site and Patient Recruitment solutions, Science 37 identified, recruited, medically qualified, and enrolled 129 patients across 36 states within an 8-week timeline, averaging 65 patients per month. As the top-enrolling site, Science 37 successfully randomized and trea
15-12G - Science 37 Holdings, Inc. (0001819113) (Filer)
EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)
EFFECT - Science 37 Holdings, Inc. (0001819113) (Filer)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
SC 13D/A - Science 37 Holdings, Inc. (0001819113) (Subject)
RESEARCH TRIANGLE PARK, N.C., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended September 30, 2023. "Our third quarter results were highlighted by continued quarterly improvements in our key profitability metrics and cash burn rate," stated David Coman, Chief Executive Officer of Science 37. "We look forward to a strong finish to the year and positive momentum headed into 2024." Quarterly Financial Highlights Gross bookings were $17.9 million for the quarter ended September 30, 2023, a 50.6%
RESEARCH TRIANGLE PARK, N.C., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), the industry-leading Metasite™ today announced it will report third quarter 2023 financial results prior to the market open on Tuesday, November 7, 2023. The Science 37 management team will host a conference call to discuss these results on November 7, 2023, at 8:30 a.m. Eastern Time. The call can be accessed by dialing 1-877-269-7751 (toll-free domestic) or 1-201-389-0908 (international) and using the Conference ID 13741458 or by utilizing the Call me™ feature using this link to request a return call for instant telephone access to the event. The live webcast may be accessed via the i
RESEARCH TRIANGLE PARK, N.C., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Science 37 Holdings, Inc. (NASDAQ:SNCE), ("Science 37"), the industry-leading Metasite™, today reported its financial results for the quarter ended June 30, 2023. "The actions we have taken over the past nine months are leading to meaningful improvements as evidenced by our sequential quarterly results including growth in gross bookings and gross profit margins along with a reduction in cash burn," stated David Coman, Chief Executive Officer of Science 37. "We look forward to finishing the year strong and continuing to position the company for sustainable financial growth and shareholder value creation." Quarterly Financial
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
4 - Science 37 Holdings, Inc. (0001819113) (Issuer)
3/A - Science 37 Holdings, Inc. (0001819113) (Issuer)